How should a newborn with a blister on or near the lip be evaluated and treated for possible neonatal herpes infection?

Evaluation and Management of Newborn Lip Blisters

A newborn with a blister on or near the lip must be urgently evaluated for neonatal herpes simplex virus (HSV) infection with comprehensive viral cultures and PCR testing, and empiric high-dose intravenous acyclovir (20 mg/kg three times daily) should be initiated immediately while awaiting results, given the devastating mortality and morbidity of untreated neonatal HSV.

Immediate Diagnostic Workup

The presence of a blister on or near the lip in a newborn is concerning for neonatal HSV infection, which can present as localized skin, eye, and mouth (SEM) disease but may progress to disseminated or CNS disease 1.

Required Specimens for HSV Testing

Obtain cultures and/or PCR from multiple sites 1:

• Surface lesions: Swab the blister fluid and base
• Mouth/nasopharynx: Viral culture or PCR
• Eyes: Conjunctival swabs
• Blood: HSV PCR (serum)
• Urine: Viral culture
• Stool or rectum: Viral culture
• Cerebrospinal fluid: HSV DNA PCR (critical - HSV-1 and HSV-2)

Critical timing note: Positive cultures from mucosal sites (mouth, nasopharynx, eyes, urine, stool/rectum) obtained >48 hours after birth indicate viral replication rather than contamination from intrapartum exposure 1.

Additional Evaluation

• Complete CSF studies: Cell count, protein, glucose, and HSV PCR - even if the infant appears well, as approximately 60% of neonates with CNS or disseminated disease lack visible vesicles 1
• Liver function tests: To assess for disseminated disease
• Blood culture: To rule out bacterial sepsis
• Complete blood count: Monitor for neutropenia

Immediate Treatment

Start Empiric Acyclovir Without Delay

Do not wait for test results to initiate treatment - the mortality of untreated disseminated neonatal HSV exceeds 80%, and early treatment dramatically improves outcomes 2, 3.

Dosing regimen 1:

• High-dose intravenous acyclovir: 20 mg/kg/dose three times daily
• Duration depends on final diagnosis:
  • 14 days for confirmed SEM disease (skin, eye, mouth only)
  • 21 days for CNS or disseminated disease

Treatment Monitoring

• For CNS disease: Do not discontinue acyclovir until repeat CSF HSV DNA PCR is negative at day 19-21 of treatment 1
• Monitor for toxicity: Neutropenia (most common in neonates receiving high-dose acyclovir - occurs in up to 46%), nephrotoxicity (6%), phlebitis 1
• Ensure adequate hydration and adjust dose for renal insufficiency

Clinical Context and Risk Assessment

Appearance of Neonatal HSV

• Vesicular rash is present in only ~80% of SEM disease and ~60% of CNS/disseminated disease 1 - absence of widespread lesions does NOT rule out serious disease
• Typical presentation timing: 9-11 days of life for disseminated disease, 10-11 days for localized disease 1
• Encephalitis occurs in 60-75% of infants with disseminated disease 1

Maternal History Considerations

While not provided in this case, maternal history is crucial:

• Highest risk (30-50% transmission): Primary maternal genital HSV near delivery 4
• Lower risk (3%): Recurrent maternal HSV or acquisition in first half of pregnancy 4
• Most mothers of infected neonates lack known HSV history 4

Common Pitfalls to Avoid

1. Waiting for test results before starting acyclovir - this delays life-saving treatment
2. Assuming a single blister means only localized disease - disseminated and CNS disease can present with minimal skin findings
3. Failing to obtain CSF - CNS involvement requires longer treatment and has worse prognosis
4. Incomplete specimen collection - all sites must be sampled to establish extent of disease
5. Stopping treatment at 14 days without confirming negative CSF PCR in cases with CNS involvement

Prognosis and Follow-up

• SEM disease with treatment: Very good prognosis, though 2-6% may develop neurologic sequelae despite apparently successful treatment 1
• CNS/disseminated disease: Significant risk of neurologic impairment even with treatment 1
• Suppressive oral acyclovir (300 mg/m² 2-3 times daily) for 6 months following acute treatment improves neurodevelopmental outcomes in CNS disease 5, 3
• Cutaneous recurrences may occur in first 6 months even after successful treatment 1

The key principle: When neonatal HSV is suspected based on any mucocutaneous lesion, immediate comprehensive evaluation and empiric high-dose IV acyclovir are mandatory to prevent mortality and reduce long-term morbidity 1.